Drugs

Emma Vidal: A new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy

Photo taken from Rony Dahan/X

Jan 26, 2024, 07:25

Emma Vidal: A new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy

Emma Vidal, Founder of DrawImpacts, shared an X post by Rony Dahan, Principal Investigator at Weizmann Institute of Science, adding:

“We had a blast working with the Rony Dahan and Yuval Shapir Itai to illustrate their latest paper on BiCE (Bispecific DC-T Cell Engager), a new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy!

Learn more about their amazing work.”

Quoting Rony Dahan‘s post:

“Together with IdoAmitLab we’re very excited to introduce BiCE (Bispecific DC-T Cell Engager)- a new platform to engineer immune cell communication for cancer immunotherapy. Led by the amazing Yuval Shapir Itai, Oren Barboy, now out in Cell Press Journal.”

Source: Emma Vidal/X and Rony Dahan/X

BiCE (Bispecific DC-T Cell Engager) cancer Cell Press Journal DrawImpacts Emma Vidal IdoAmitLab immunotherapy OncoDaily Oncology Oren Barboy Rony Dahan Yuval Shapir Itai

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage